The revised EU GMP Annex 1 has rapidly become one of the most influential regulatory updates in sterile medicinal product manufacturing. Its impact is global, its expectations far reaching, and its interpretation still evolving. In a recent episode of the Pharma Conversations podcast, we sat down with Jim Polarine, Principal Consultant at STERIS one of the industry’s most respected voices on contamination control, to explore how organisations are navigating Annex 1 in real world environments.

Several themes repeatedly emerged: the criticality of a robust contamination control strategy (CCS), the growing maturity gap between regions, the importance of a robust risk assessment, and the operational challenges that continue to surface in cGMP (current Good Manufacturing Practices) drug and device manufacturing facilities. What follows is a comprehensive analysis of the key takeaways from Jim’s insights offering a practical, experience driven perspective on Annex 1 implementation today.

CCS Is No Longer a Document – It’s a Mindset

Contamination control strategy is the backbone of Annex 1. It is not a checklist, not a binder on a shelf, and not a regulatory afterthought. It is a holistic, cross functional framework that must integrate every aspect of sterile manufacturing.